Amygdalin analogs for the treatment of psoriasis
- 1 May 2013
- journal article
- review article
- Published by Future Science Ltd in Future Medicinal Chemistry
- Vol. 5 (7), 799-808
- https://doi.org/10.4155/fmc.13.27
Abstract
Psoriasis is one of the most prevalent immune-mediated illness worldwide. The disease can still only be managed rather than cured, so treatments are aimed at clearing skin lesions and preventing their recurrence. Several treatments are available depending on the extent of the psoriatic lesion. Among the topical treatments corticostereoids, vitamin D3 analogs and retinoids are commonly used. However, these treatments may have adverse effects in the long term. Conversely, systemic conventional treatments include immunosuppresors such as cyclosporin or methotrexate associated with high toxicity levels. Biologicals are alternative therapeutical agents introduced in the last 10 years. These include fusion proteins or monoclonal antibodies designed to inhibit the action of specific cytokines or to prevent T-lymphocyte activation. However, due to recent knowledge on the etiology of the disease, diverse new small molecules have appeared as promising alternatives for the treatment of psoriasis. Among them, inhibitors of JAK3, inhibitors of PDE 4 and amygdalin analogs. The latter are promising small molecules presently in preclinical studies which are the object of the present report.Keywords
This publication has 30 references indexed in Scilit:
- Psoriasis: from bed to bench and backNature Biotechnology, 2011
- Five Bitter Compounds Display Different Anti-inflammatory Effects through Modulating Cytokine Secretion Using Mouse Primary Splenocytes in VitroJournal of Agricultural and Food Chemistry, 2010
- Psoriasis: from pathogenesis to novel therapeutic approachesClinical Science, 2010
- Psoriasis marketNature Reviews Drug Discovery, 2009
- Patented small molecules against psoriasisExpert Opinion on Therapeutic Patents, 2009
- Laetrile for cancer: a systematic review of the clinical evidenceSupportive Care in Cancer, 2006
- PsoriasisThe New England Journal of Medicine, 2005
- Psoriasis: emerging therapeutic strategiesNature Reviews Drug Discovery, 2005
- A Clinical Trial of Amygdalin (Laetrile) in the Treatment of Human CancerThe New England Journal of Medicine, 1982
- Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue.Proceedings of the National Academy of Sciences of the United States of America, 1981